Vivitrol Approved to Prevent Opioid Relapse

powered by healthline

Average Ratings

Injected drug blocks brain's opioid receptors

WEDNESDAY, Oct. 13 (HealthDay News) -- Vivitrol (naltrexone extended release) has been approved by the U.S. Food and Drug Administration to treat and prevent relapse among opioid-dependent people who have completed a detoxification program.

The drug blocks brain receptors for opioids, which include morphine and heroin. In 2006, Vivitrol was approved to treat dependence on alcohol, the agency said in a news release.

There must be no opioids in a patient's system when treatment with Vivitrol is begun, or a user may develop symptoms of opioid withdrawal. And those who begin re-using opioids once treatment with Vivitrol is started risk opioid overdose, the FDA warned.

Treatment with once-monthly Vivitrol should be administered only by a physician using specially provided needles, the agency said. Potential side effects include nausea, fatigue, headache, dizziness, nausea, loss of appetite, painful joints and muscle cramps.

Vivitrol is manufactured by Alkermes Inc.

More information

The U.S. National Library of Medicine has more about drug abuse.

-- Scott Roberts
Copyright © 2010 HealthDay. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools

What is a reference number?

When you register on this site, you are assigned a reference number. This number contains your profile information and helps UnitedHealthcare identify you when you come back to the site.

If you searched for a plan on this site in a previous session, you might already have a reference number. This number will contain any information you saved about plans and prescription drugs. To use that reference number, click on the "Change or view saved information" link below.

You can retrieve information from previous visits to this site, such as saved drug lists and Plan Selector information.